Skip to content

Comparison of visual acuity and macular thickness in patients with macular edema cuased by branch retinal vein occlusion treated with intravitral avastin and intravitral avastin and tissue plasminogen activator

Comparison of visual acuity and macular thickness in patients with macular edema cuased by branch retinal vein occlusion treated with intravitral avastin and intravitral avastin and tissue plasminogen activator

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014072618596N1
Enrollment
50
Registered
2014-08-21
Start date
2014-02-03
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion. Retinal vein occlusion_ partial

Interventions

Intervention 1: For the 25 patients Intravitral Avastin and Tissue Plasminogen Activator will be injected. Intervention 2: For the 25 patients Intravitral Avastin will be injected.
Treatment - Surgery
For the 25 patients Intravitral Avastin and Tissue Plasminogen Activator will be injected
For the 25 patients Intravitral Avastin will be injected

Sponsors

Vice chancellor for Research and Technology, Tabriz University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Having the diagnosis of BRVO. 2) Slit lamp examination: macular edema. 3) Snellen visual acuity: vision worse than 20/40. 4) Optical coherence tomography finding: central macular thickness of 250µm and over on. Exclusion: 1) BRVO associated with vitrous hemorrhage. 2) previous treatment with laser photocoagulation. 3) History of previous vitrectomy. 4)Intraocular pressure more than 21 mmhg. 5) Uncontrolled diabetes. 6) Systemic blood pressure. 7) Uveitis. 8) Any evidence of posterior vitrous detachment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Visual acuity. Timepoint: Before intervention, one month, 3 months, 6 months after intervention. Method of measurement: Snellen chart.;Central macular thickness. Timepoint: Before intervention, one month, 3 months, 6 months after intervention. Method of measurement: Optical Coherence tomography.

Secondary

MeasureTime frame
Endophthalmitis. Timepoint: 1, 3 and 6 month after intervention. Method of measurement: clinical.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Sadegi Karim

Tabriz University Of Medical Science

sadegik@tbzmed.ac.irpeymanpourreza1359@gmail.com+98 41 1657 7331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026